Benefits
Fasting blood glucose reduction (class evidence)
Cinnamon class evidence: clinical trials in adults with type 2 diabetes (1, 3, or 6 g/day for 40 days) documented 18-29% reductions in fasting serum glucose vs placebo. Effects also documented in pre-diabetes and elevated baseline glucose populations. Akay's FenuMat® bioavailability enhancement supports effects at lower clinical doses (120-500 mg standardized extract).
Triglyceride and cholesterol improvement
Cinnamon class evidence documents reductions in triglycerides (23-30%), LDL cholesterol (7-27%), and total cholesterol (12-26%) after 40 days in type 2 diabetics. The multi-marker lipid improvement is meaningful for metabolic syndrome and cardiovascular risk management — particularly when combined with the glycemic effects.
Post-prandial glucose suppression
Cinnamon has documented acute effects on post-prandial blood glucose responses — flattening the glycemic curve after meals via α-amylase and α-glucosidase enzyme inhibition (an acarbose-like mechanism). Effect particularly valuable for adults with normal fasting glucose but elevated post-meal glucose responses — an early sign of metabolic dysfunction.
Insulin sensitivity enhancement
Cinnamon is purported to be a natural insulin sensitizer — supported by both in vitro and animal studies. Mechanism involves insulin receptor auto-phosphorylation/de-phosphorylation, GLUT-4 receptor synthesis and translocation, and modulation of hepatic glucose metabolism via Pyruvate kinase and PEPCK. Multiple pathway effects support sustained glycemic control.
FenuMat® bioavailability enhancement
FenuMat® is a patented self-emulsifying fenugreek soluble fiber hydrogel technology used across Akay's portfolio (Asafin, Tenzara, Cinnamon FenuMat). The scaffold enhances bioavailability of lipophilic cinnamon compounds (cinnamaldehyde and polyphenols) while providing controlled intestinal release. Mechanism supports lower effective doses vs raw cinnamon powder.
Fenugreek synergistic glucose-lowering
Fenugreek (Trigonella foenum-graecum) — the FenuMat® scaffold component — has independent class evidence for glucose-lowering effects via 4-hydroxyisoleucine (an amino acid with insulin-secretagogue activity) and soluble fiber (slowing carbohydrate absorption). The fenugreek soluble fiber provides synergistic metabolic support alongside the cinnamon bioactives.
Reduced coumarin exposure concerns
Standardized cinnamon extract reduces coumarin exposure vs raw cinnamon powder. EFSA's coumarin limit is 0.1 mg per kg body weight per day (~7 mg/day for a 70 kg adult). Cassia cinnamon powder can contain higher coumarin levels — standardized extracts with lower coumarin support safer long-term daily use vs spice-level dosing concerns.
Mechanism of action
α-Amylase and α-glucosidase inhibition
Cinnamon inhibits intestinal α-amylase and α-glucosidase enzymes — the same target as the pharmaceutical diabetes drug acarbose. These enzymes break down dietary starches and disaccharides into absorbable glucose. Inhibition slows carbohydrate digestion and blunts post-prandial glucose spikes. Mechanism explains the acute post-meal glucose effects.
GLUT-4 receptor synthesis and translocation
GLUT-4 is the insulin-responsive glucose transporter that moves from intracellular vesicles to the cell membrane upon insulin signaling, enabling glucose uptake into muscle and fat cells. Cinnamon supports GLUT-4 receptor synthesis and translocation — enhancing glucose uptake even at the same insulin levels. Mechanism contributes to the insulin sensitivity effects.
Insulin receptor phosphorylation modulation
Cinnamon modulates insulin receptor auto-phosphorylation and de-phosphorylation — improving the receptor's insulin signaling fidelity. The mechanism addresses one of the fundamental defects in type 2 diabetes (insulin receptor dysfunction) rather than just compensating with higher insulin levels.
PPAR-γ expression modulation
Cinnamon alters PPAR-γ (peroxisome proliferator-activated receptor gamma) expression — a transcription factor involved in lipid metabolism, glucose homeostasis, and inflammation. PPAR-γ is also the target of the pharmaceutical diabetes drug class thiazolidinediones (pioglitazone, rosiglitazone). Cinnamon provides milder PPAR-γ modulation.
Hepatic glucose metabolism modulation
Cinnamon modulates hepatic glucose metabolism through changes in Pyruvate kinase (PK) and Phosphoenol Pyruvate Carboxykinase (PEPCK) — key enzymes regulating glucose production by the liver. Hepatic glucose production (gluconeogenesis) is elevated in diabetes; reducing it supports better fasting glucose control.
Clinical trials
Pioneering clinical trial evaluating Cinnamomum cassia at three doses (1, 3, or 6 g/day) for 40 days in subjects with type 2 diabetes. Foundational evidence for cinnamon's glycemic effects. in Diabetes Care (Khan et al.) — one of the most-cited cinnamon trials.
60 Pakistani participants with type 2 diabetes. 40-day intervention with three dose-comparison groups.
Significant reductions in fasting blood sugar at all three doses (18-29%), with greater reduction at higher doses. Cholesterol (including LDL) reduced 7-27%. Triglycerides reduced 23-30%. Total cholesterol reduced 12-26%. Established cinnamon as a potential dietary adjunct for type 2 diabetes management. Limitations: single-population (Pakistani), no HbA1c measurement.
Randomized crossover clinical trial evaluating acute post-prandial effects of cinnamon on glucose, insulin, glucose-dependent insulinotropic polypeptide (GIP), GLP-1, and ghrelin in healthy subjects. Multiple cinnamon doses tested. Published in PMC.
Healthy subjects. Crossover design with 1 g and 3 g cinnamon doses on standardized meal.
Raw cinnamon dissolved in water decreased meal-induced large glucose spikes (peak-rise of +87 mg/dL and Δ1-hour glycemia of +79 mg/dL) and the hyperglycemic blood glucose peak. Effects via α-amylase/α-glucosidase inhibition (acarbose-like mechanism). Capsule format reduced effects vs powder-in-water — supporting FenuMat® formulation advantage for bioavailable delivery.
Class evidence from multiple pooled analyses of cinnamon clinical trials. Pooled analyses examining glycemic control (fasting glucose, HbA1c, post-prandial glucose) and lipid profile across dozens of cinnamon trials. Provides broad evidence base for metabolic applications.
Various — adults across multiple cinnamon trials in pre-diabetic, type 2 diabetic, and metabolic syndrome populations.
Cinnamon consistently produces modest improvements in fasting plasma glucose and modest reductions in HbA1c across pooled analyses. Effects in pre-diabetes and treatment-naïve type 2 diabetes appear larger than in those on insulin-sensitizing medications. Multiple mechanism pathways (GLUT-4, insulin receptor, α-glucosidase, PPAR-γ) support sustained effects. FenuMat® formulation enhances bioavailability.